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Dear Editor,
We greatly enjoyed reading the thought-provoking article
by Lopes et al. in a recent issue of your esteemed journal (1).
Interestingly, in recent years, data have emerged regarding
a role for EML4 (echinoderm microtubule-associated pro-
tein-like 4)–ALK (anaplastic lymphoma kinase) in persona-
lized treatment for advanced non-small-cell lung cancer
(NSCLC) (2,3). EML4-ALK undergoes constitutive dimer-
ization through the interaction between the coil-coil
domains within the EML4 region of each monomer, thereby
activating ALK and promoting oncogenic activity (4).
EML4-ALK fusion, EGFR, and KRAS mutations are all
mutually exclusive, implicating ALK rearrangement as a
potential therapeutic target in EGFR wild-type and KRAS
wild-type lung cancers (5). Nevertheless, Lopes’ study (1)
raises some interesting questions. Was patient selection for
the study carried out appropriately? Did the study provide
a representative sample of the Latin-American population,
as described in the paper? Could immunohistochemistry be
substituted for fluorescence in situ hybridization? Which
technique is more appropriate for clinical practice? Should
we perform this analysis in a specific subset of patients or in
all advanced NSCLC patients? In addition, it is interesting
to speculate whether EML4-ALK-targeted therapies may be
relevant for clinicians, although patients positive for the
EML4–ALK fusion protein frequently present at an
advanced clinical stage, and their tumors demonstrate a
solid adenocarcinoma pattern and signet ring cells (5).
Furthermore, the presence of the EML4-ALK fusion
oncoprotein is associated with nonsmokers or light smokers
and is more frequent in younger patients (5). Thus, young,
non-smoking patients and patients with adenocarcinoma
tumor histology may indeed benefit from an EML4-ALK
diagnostic test. Recently, the U.S. Food and Drug
Administration approved crizotinib, which is a small-
molecule inhibitor of the ALK tyrosine kinase, as a
treatment for patients with locally advanced or metastatic
NSCLC expressing the EML4–ALK fusion protein (2). The
results were recently reported for a clinical trial in which 82
ALK-positive patients were evaluated for the therapeutic
efficacy of crizotinib (6). The results were quite promising,
demonstrating an overall response rate of 57% (46 partial
responses and 1 complete response) and a 33% stable
disease rate (27 patients) (2). Of the 82 patients, 63 (77%)
continued to receive crizotinib at the time of data cut off,
and the estimated probability of a 6-month progression-free
survival was 72% (2). Thus, the refined understanding of the
NSCLC molecular profile described over the last decade has
proven to be an important tool to help medical oncologists
develop new approaches for NSCLC treatment. Despite the
small frequency of advanced NSCLC patients who present
with EML4-ALK fusion (2.4 to 6.7%) (1), we believe that all
patients in this setting should have the opportunity to
receive such innovative therapies and approaches.
However, further studies are warranted to establish the
appropriate pharmaco-economic profiles.
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